menu search

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau ta...

October 25, 2023, 2:51 pm

Matinas biopharma to present at two investment conferences in october 2023

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on re...

September 28, 2023, 7:00 am

Agilent not as agile as hoped as life sciences demand proves to be less than invincible

Demand from biopharmas for life sciences equipment has not sustained high expectations in 2023, leading to weaker growth and negative revisions for co...

September 26, 2023, 4:14 pm

Matinas biopharma announces notification of nyse american continued listing deficiency

BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on r...

September 22, 2023, 9:25 pm

Wave life sciences: excellent early data, major collaborations, needs cash

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutation...

September 12, 2023, 5:09 pm

Dyne therapeutics: muscle disease oligo therapy developer in early stages

Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular D...

September 10, 2023, 5:25 am

Pepgen announces presentations at the 2023 myotonic dystrophy foundation annual conference, ottawa neuromuscular disease meeting, and h.c. wainwright 25th annual global investment conference

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of ...

September 1, 2023, 8:00 am

Roquefort files to patent anti-cancer therapeutics globally

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has announced the successful filing of a global patent for its anti-cancer therapeutics. Once approv...

August 14, 2023, 3:56 am

Aligos therapeutics announces research collaboration and development agreement with xiamen amoytop biotech co. ltd. for use of aligos’ oligonucleotide platform for the treatment of liver diseases

SOUTH SAN FRANCISCO, Calif., May 12, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical s...

May 12, 2023, 9:05 pm

Avidity biosciences: helping deliver oligonucleotides outside liver cells

Avidity Biosciences, Inc. is a leader in antibody oligonucleotide conjugate technology. This technology...

March 9, 2023, 3:03 pm

Diving into dyne therapeutics

Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the back of good news from a rival, more than triplin...

January 19, 2023, 5:01 pm

Biogen (biib) inks licensing deal for implantable medical device

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neur...

January 5, 2023, 3:48 pm

Avidity biosciences: unique antibody-oligonucleotide conjugate technology

Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-...

December 22, 2022, 5:22 am

Wave, gsk enter strategic collaboration

Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic colla...

December 13, 2022, 8:04 am

Proqr to present its axiomer® rna editing technology at the oligonucleotide and peptide therapeutics conference (tides europe) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedica...

November 14, 2022, 4:30 pm

Avidity biosciences to participate in upcoming investor conferences

SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of ...

September 1, 2022, 9:05 am

Exicure to present at upcoming tides usa oligonucleotide & peptide therapeutics conference

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022....

May 9, 2022, 7:00 am


Search within

Pages Search Results: